Revlimid (lenalidomide) is an immunomodulatory anti-cancer treatment developed by Celgene for multiple myeloma and other diseases.| Rare Cancer News
Chimeric antigen receptor (CAR) T-cell therapy is a new type of immunotherapy that uses the body's own immune system to target cancer cells.| Myeloma Research News
Marisa Wexler is a senior science writer for Myeloma Research News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of myeloma topics.| Myeloma Research News